Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

30 Oct 2007 10:02

ViaLogy PLC30 October 2007 30 October 2007 ViaLogy plc AGM statement At the Annual General Meeting of ViaLogy PLC (VIY), the AIM-quoted technologycompany that is a leading innovator of network-centric, real time signalprocessing platforms for sensor applications, to be held at 10am today, theChairman, Terry Bond, will make the following statement. "It has been a year since shareholders approved the acquisition of the remainderof ViaLogy's share capital and the change of name to ViaLogy plc. During theyear the company has achieved a number of significant technical and productmilestones and the transition from research and development-driven activities tothe commercialisation of the technology is well underway. Over the next year ViaLogy will roll-out several products, principally SPM,MicroSPM and MPEX, initially targeting the defence, oil & gas and enterprisemarkets. These applications are based on ViaLogy's proprietary,patent-protected Quantum Resonance Interferometry (QRI) signal processingtechnology that enables the detection and interpretation of very weak signalsfrom large amounts of information and background noise. Ultimately SPM providesa solution to the problem of sensor integration. SPM, Sensor Policy Manager, is an enterprise-grade software product for sensorprocessing and interoperability. Unlike other sensor management solutions thatwork only with sensors from a single vendor, ViaLogy SPM software automaticallydiscovers network-attached sensors from any vendor, fuses and normalises theirinputs for central monitoring, and invokes real-time actions based oncustomer-defined policies. The network-centric approach provides measurablebenefits for security, safety and surveillance. The technology can integrate upto thousands of sensors connected to wireless and wired networks without delaysor loss of coverage. One of the early adopters of the SPM technology was Cisco Systems, which hasimplemented the technology at its San Jose campus to support safety and securityoperations, enabling the automation of complex facility operations. ViaLogy hasalso negotiated contracts for further SPM installations in the US and Taiwan. MicroSPM, is a compact, hardware-based solutions for real-time video and sensordata processing. It is designed to automate and improve the speed andeffectiveness of security and surveillance activities, such as face recognitionin crowds; human, object and vehicle detection and counting; and license platereading, in particular under difficult environment conditions. Reducingreliance on multiple human operators for analysis and decision-making. MPEX (Multi Parallax Exploitation) Electronic Eye, is a major advancement incomputer vision and video surveillance technology. In development with BoeingPhantom Works, the electronic eye is capable of 360 degree video processing,based on bionic principles that mimic the optical movements of some insects andreptiles. Initial applications for this technology will be for the detection ofvery fast moving targets such as missile interceptors, deployment of fast movingground vehicles and airborne platforms like unmanned aerial vehicles. Beyond these products other opportunities exist for ViaLogy's technology asannounced during the year. A technical breakthrough to improve the stability andperformance of miniature vibratory gyroscopes, achieved in collaboration withNASA's Jet Propulsion Laboratory and Boeing, which has wider applications in theemerging Micro Electro-Mechanical Systems (MEMS) market; the development of thedual-beam Reverse Photo-Acoustic Spectrometer (REPAS) with the Oak RidgeNational Laboratory for the detection of chemical, biological, radiological,nuclear and explosive materials; and, selection by the US Department of Defenseto provide a command and control platform for joint experiments to support thenext generation Joint Force Protection Advanced Security (JFPASS). An investment is being made to establish a strong sales and marketing team inorder for the Company to be able to exploit the opportunities available to it bybuilding relationships with potential partners and identifying global saleschannels. As you can see it is an exciting time for ViaLogy and the Board is enthusiasticand confident about the progress the Company will make over the next year andbeyond." End For further information please contact: ViaLogyTerry Bond, Chairman +44 (0)1235 834734 or 07860 842756Seymour Pierce Mark Percy, Nominated Adviser +44 (0)20 7107 8000Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications. ViaLogy is currently deploying and designingcomputational systems, powered by its patented technologies, for applications inlife sciences, public safety and security, surveillance, defence andgeoseismology. Vialogy focuses on market driven problems where automation,timeliness, quality and reliability of information processing are essential.ViaLogy's core competency incorporates rapidly and accurately detecting weaksignals buried in high noise background and clutter. This technology can beemployed to solve problems involving sensor integration and information overloadchallenges involving video, telephony and control sensors, as well as forenhancement of numerous signal processing applications. For more information,visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Apr 20204:40 pmRNSSecond Price Monitoring Extn
6th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20203:00 pmRNSIssue of Share Options
25th Mar 20207:00 amRNSContract manufacturing agreement for COVID-19 test
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:36 pmRNSPrice Monitoring Extension
13th Mar 202011:51 amRNSHolding(s) in Company
10th Mar 20207:00 amRNSAcquisition of French distribution channel
17th Feb 20207:00 amRNSCE Marking Technical File submission
14th Feb 202011:00 amRNSMedilink Award win for Outstanding Achievement
14th Feb 20207:00 amRNSTGA approves DPYD for sale in Australia
5th Dec 201912:10 pmRNSThe Healthcare+ Expo Taiwan
2nd Dec 20197:00 amRNSHalf-year Report
29th Nov 201912:05 pmRNSBionow Double Award Win
28th Nov 20197:00 amRNSOpening of New Facilities and Corporate HQ
15th Nov 20197:00 amRNSPrivate Investor Presentation
12th Nov 201910:12 amRNSNotice of Results
6th Nov 20191:52 pmRNSCapital Markets Day
1st Nov 20197:00 amRNSDirector/PDMR Shareholding
31st Oct 20197:00 amRNSLaunch of Yourgene FlexT Analysis Software
30th Oct 20197:00 amRNSIssue of Share Options
15th Oct 20197:00 amRNSAmerican Society of Human Genetics Annual Meeting
14th Oct 20197:00 amRNSHalf year trading update
1st Oct 20197:00 amRNSPrivate Investor Presentation
26th Sep 20197:00 amRNSCE-IVD Certification renewal
18th Sep 20197:00 amRNSLaunch of DPYD chemotoxicity diagnostic assay
17th Sep 20195:50 pmRNSResult of AGM
17th Sep 20197:00 amRNSAGM Statement
20th Aug 20197:00 amRNSNotice of AGM
19th Aug 201910:35 amRNSChange of Registered Office
16th Aug 20193:49 pmRNSHolding(s) in Company
16th Aug 20199:06 amRNSDirectorate Change
12th Aug 20197:00 amRNSAmendment to Share Options
1st Aug 20197:00 amRNSDirector/PDMR Shareholding
29th Jul 20197:00 amRNSAppointment of Director
10th Jul 20197:00 amRNSFinal Results, Business Update and Director Change
27th Jun 20197:00 amRNSNotice of Results
24th Jun 20197:00 amRNSYourgene participates in key global conferences
3rd Jun 20197:01 amRNSDirector's dealing
3rd Jun 20197:00 amRNSIssue of Share Options
9th May 20194:07 pmRNSDirector's dealing
9th May 20197:00 amRNSDirectors' dealing & warrant extension
1st May 20198:05 amRNSTotal Voting Rights
26th Apr 20195:12 pmRNSHolding(s) in Company
26th Apr 20195:01 pmRNSHolding(s) in Company
25th Apr 20194:40 pmRNSCompletion of Acquisition
18th Apr 20197:00 amRNSResults of Placing and Subscription
17th Apr 20194:50 pmRNSAppointment of Sole Corporate Broker
17th Apr 20194:48 pmRNSProposed Acquisition, Placing & Subscription
8th Apr 20197:00 amRNSFull-year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.